Dr. Andreas von Falck

Dr. Andreas von Falck


Email [email protected]​hoganlovells.com

Phone +49 211 13 68 326

Fax +49 211 13 68 100

LanguagesEnglish, Italian, French, German

Practice groupIntellectual Property, Media, and Technology

He is as brilliant as he always was. He has tremendous knowledge and experience, having been involved in huge cases, and is extremely well connected in the community. He’s a very likeable and approachable person too.”

IAM Patent 1000, 2018

Andreas von Falck is a trial lawyer with a track record for developing successful litigation strategies. He loves technology and science and finding ways to convey simple messages to the decision makers. In its 2019 edition, IAM wrote about him: “a defining individual in the world of German intellectual property” who’s “advocacy can flip the outcome of a case, which is precisely why he is so sought after.” 

Andreas von Falck is part of our global Patent Litigation practice. He has an excellent track record in litigating patents in all areas of patent law but with a particular focus on the life sciences, chemical, and high-tech industries. Andreas has advised many of the world's leading companies in patent litigation in Germany and has had conduct of a vast number of cross border proceedings including all parts of Europe. In addition, he has had a number of remarkable wins in validity appeals before the German Federal Supreme Court.

As part of our multiple award winning global patent litigation practice, Andreas is recommended for patent litigation by Chambers Global World's Leading Lawyers, Who's Who Legal, Managing Intellectual Property, Legal 500, and JUVE, the leading German legal directory. Recognised for offering first class, innovative solutions, He is praised for his "analytical approach and availability" (Chambers 2018) and as "extremely knowledgeable and one of the top litigators in Germany, if not the top."(Chambers 2017)

Awards and recognitions


Included for Health Care Law
Edition Best Lawyers™ in Germany


Intellectual Property: Patent Litigation, Leading Individual
Legal 500 EMEA


Industry Focus: Healthcare and Life Sciences
Legal 500 EMEA


Included for Litigation
Edition Best Lawyers™ in Germany


Included for Pharmaceuticals Law
Edition Best Lawyers™ in Germany


Included for Intellectual Property Law
Edition Best Lawyers™ in Germany


Acritas Star
Acritas Stars Independently Rated Lawyers


Intellectual Property: Patent Litigation (Germany)
Chambers Global


Listed as Patent Star
Managing Intellectual Property IP STARS


Leading Senior Partner in Patent Litigation
JUVE handbook


Leading individual for Patent Law: Dispute Resolution
Legal 500 Germany


Top ranked lawyer for Patent Litigation
Chambers Global

Education and admissions


Dr. iur., University of Freiburg, 1997

University of Geneva

University of Tuebingen

Representative experience

Working for many of the world's largest companies in the life sciences and chemical industries and arguing for high tech companies in FRAND disputes.

Representing a leading US pharma company in patent nullity and infringement proceedings up to the Federal Supreme Court regarding its world leading antidepressant.

Acting for a US medical devices manufacturer in European litigation and coordinating Asian and US litigation regarding neurovascular implants.

Acting for a world leading pharmaceutical and biotech company regarding several of its blockbuster biotech products.

Acting for leading chemical company in patent litigation with competitor in Germany and the EPO.

Acting for a leading US drug manufacturer in European Court of Justice regarding supplementary protection certificate.

Acting for a leading global handset manufacturer on all aspects of defending against one of the world's largest non-practicing entities.

Representing a Japanese high-tech company against "troll" a attack.

Advising a world leading industrial on its worldwide patent strategy and implementation.

Advising a diagnostics company on patenting strategy.

Assisting a top-ten pharma company on obtaining and defending secondary protection for new indications of its anti-cancer medicament.

Loading data